Sanofi (NASDAQ:SNY) is one of the Best Affordable Stocks to Buy According to Analysts. On December 24, Sanofi (NASDAQ:SNY) announced entering into a definitive agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a company that has a marketed hepatitis B vaccine and a differentiated shingles vaccine candidate.
Management noted that the acquisition aligns with the company’s strategy by expanding its presence in adult immunization through Dynavax’s candidates. Moreover, HEPLISAV-B is the only two-dose adult hepatitis B vaccine approved in the US. The drug is administered in two monthly doses for faster protection compared to three-dose competitors over six months.
The deal is valued at $15.50 per share in cash, which totals to roughly $2.2 billion in equity value. Moreover, the deal has already been unanimously approved by the Dynavax board of directors and is expected to close in the first quarter of 2026. Management noted that this deal will not impact Sanofi’s (NASDAQ:SNY) financial guidance for 2025.
That said, Wall Street has a positive outlook on the stock, with analysts’ 12 month price target reflecting more than 26% upside from the current level. Recently, on December 17, Steve Scala from TD Cowen reiterated a Hold rating on the stock with a price target of $57.
Sanofi (NASDAQ:SNY) is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions across pharmaceuticals, vaccines, and consumer healthcare.
While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
